SXTC

China SXT Pharmaceuticals, Inc. SXTC

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $7.0M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Revenue

$1.14M

Quarter to Mar 31

Net income

$-6.21M

Quarter to Mar 31

Top Institutional Holders

as of Q3 2024
$6.4K total
BANK OF MONTREAL /CAN/
$6.4K0.0%
PROEQUITIES, INC.
$0New
ACADIAN ASSET MANAGEMENT LLC
$0-86.3%
See all 3 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

FY 2026
EDGAR

Net Income

FY 2026
EDGAR

EPS (Diluted)

FY 2026
EDGAR

ROIC

FY 2026
EDGAR

Debt/Equity

FY 2026
EDGAR

Loading ratio trend…

SXTC key financials by period

Reported revenue, net income and operating margin by fiscal year, from China SXT Pharmaceuticals, Inc.'s annual filings on SEC EDGAR.

China SXT Pharmaceuticals, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2026$1.1M$-6.2M—
FY 2025$1.7M$-3.3M-154.0%
FY 2024$1.9M$-3.1M-130.4%
FY 2023$2.0M$-5.9M—
FY 2022$2.6M$-5.7M-199.4%
FY 2021$4.8M$-2.7M-46.0%
Source: SXTC filings on SEC EDGAR →

About China SXT Pharmaceuticals, Inc. (SXTC): stock profile, AI score and financials

China SXT Pharmaceuticals, Inc. (SXTC) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. SXTC is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $7.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (FY 2026), China SXT Pharmaceuticals, Inc. reports quarterly revenue of $1.1M, net income of $-6.2M. SXTC trades on the Nasdaq exchange and files with the SEC under CIK 1723980. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SXTC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for China SXT Pharmaceuticals, Inc. directly from SEC EDGAR.

SEC EDGAR: CIK 1723980 →